Tibolone and Breast Tissue: a Review.

Female Humans Estrogen Receptor Modulators / adverse effects Norpregnenes / adverse effects Hormone Replacement Therapy / adverse effects Breast Neoplasms / chemically induced
Breast Breast cancer Breast density Hormone replacement therapy Menopause Tibolone

Journal

Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249

Informations de publication

Date de publication:
12 2023
Historique:
received: 23 02 2023
accepted: 09 07 2023
medline: 4 12 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

The safety profile of hormone replacement therapy (HRT) on breast is still controversial. Tibolone is an option of treatment for climacteric syndrome of postmenopausal women. Its risk profile on breast is debated. This is an updated narrative review focusing on the impact of tibolone on breast. Particularly, we will report data from major preclinical and clinical studies regarding the effects of the use of this compound on breast tissue and breast density. Moreover, we will analyze and discuss the most relevant findings of the principal studies evaluating the relationship between tibolone and breast cancer risk. Our purpose is making all clinicians who are particularly involved in women's health more aware of the effects of this compound on breast and, thus, more experienced in the management of menopausal symptoms with this drug. According to the available literature, tibolone seems to be characterized by an interesting safety profile on breast tissue.

Identifiants

DOI: 10.1007/s43032-023-01295-9 PMID: 37450250
pubmed: 37450250
doi: 10.1007/s43032-023-01295-9
pii: 10.1007/s43032-023-01295-9
doi:

Substances chimiques

tibolone FF9X0205V2
Estrogen Receptor Modulators 0
Norpregnenes 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3403-3409

Informations de copyright

© 2023. The Author(s), under exclusive licence to Society for Reproductive Investigation.

Références

Rossouw JE, Anderson GL, Prentice RL, AZ LC, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://doi.org/10.1001/jama.288.3.321 .
doi: 10.1001/jama.288.3.321 pubmed: 12117397
The NAMS. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.
doi: 10.1097/GME.0000000000000921
Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas. 2004;49(1):S5–S15. https://doi.org/10.1016/j.maturitas.2004.06.022 .
doi: 10.1016/j.maturitas.2004.06.022 pubmed: 15351102
Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol. 1994;49(4-6):311–8. https://doi.org/10.1016/0960-0760(94)90273-9 .
doi: 10.1016/0960-0760(94)90273-9 pubmed: 8043494
Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril. 2002;78(2):351–9. https://doi.org/10.1016/s0015-0282(02)03203-x .
doi: 10.1016/s0015-0282(02)03203-x pubmed: 12137874
Pasqualini JR, Chetrite GS. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol. 1999;69(1-6):287–92. https://doi.org/10.1016/s0960-0760(99)00082-5 .
doi: 10.1016/s0960-0760(99)00082-5 pubmed: 10419004
de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 2001;183(1-2):55–62. https://doi.org/10.1016/s0303-7207(01)00606-2 .
doi: 10.1016/s0303-7207(01)00606-2 pubmed: 11604225
Kandouz M, Lombet A, Perrot JY, Jacob D, Carvajal S, Kazem A, Rostene W, Therwath A, Gompel A. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol. 1999;69(1-6):463–71. https://doi.org/10.1016/s0960-0760(99)00069-2 .
doi: 10.1016/s0960-0760(99)00069-2 pubmed: 10419026
Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res. 1997;17(1A):135–40.
pubmed: 9066643
Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol Endocrinol. 2010;26(11):804–14. https://doi.org/10.3109/09513590.2010.495437 .
doi: 10.3109/09513590.2010.495437 pubmed: 20586550
Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76(1-5):231–8. https://doi.org/10.1016/s0960-0760(01)00044-9 .
doi: 10.1016/s0960-0760(01)00044-9 pubmed: 11384882
Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause. 2002;9(6):422–9. https://doi.org/10.1097/00042192-200211000-00007 .
doi: 10.1097/00042192-200211000-00007 pubmed: 12439101
Desreux J, Kloosterboer H, Noël A, Frankenne F, Lemaire M, Putman M, Foidart JM. Effects of tibolone on sulfatase pathway of estrogens metabolism and on growth of MCF-7 human breast tumors implanted in ovariectomized nude mice. Gynecol Obstet Invest. 2007;63(1):31–8. https://doi.org/10.1159/000094917 .
doi: 10.1159/000094917 pubmed: 16899995
Reed MJ, Kloosterboer HJ. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas. 2004;48(Suppl 1):S4–6. https://doi.org/10.1016/j.maturitas.2004.02.013 .
doi: 10.1016/j.maturitas.2004.02.013 pubmed: 15337241
de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003;68(1):21–30. https://doi.org/10.1016/s0039-128x(02)00112-5 .
doi: 10.1016/s0039-128x(02)00112-5 pubmed: 12475720
Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol. 1976;126(6):1130–7. https://doi.org/10.2214/ajr.126.6.1130 .
doi: 10.2214/ajr.126.6.1130 pubmed: 179369
Boyd NF. Mammographic density and risk of breast cancer. Am Soc Clin Oncol Educ Book. 2013. https://doi.org/10.1200/EdBook_AM.2013.33.e57 .
Tice JA, Bissell MCS, Miglioretti DL, Gard CC, Rauscher GH, Dabbous FM, Kerlikowske K. Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat. 2019;175(2):519–23. https://doi.org/10.1007/s10549-019-05167-2 .
doi: 10.1007/s10549-019-05167-2 pubmed: 30796654 pmcid: 7138025
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30. https://doi.org/10.1002/sim.1668 .
doi: 10.1002/sim.1668 pubmed: 15057881
McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol. 1994;163(2):311–5. https://doi.org/10.2214/ajr.163.2.8037021 .
doi: 10.2214/ajr.163.2.8037021 pubmed: 8037021
Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy. Surgery. 1997;122(4):669–73; discussion 673-4. https://doi.org/10.1016/s0039-6060(97)90072-6 .
doi: 10.1016/s0039-6060(97)90072-6 pubmed: 9347841
Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001;285(2):171–6. https://doi.org/10.1001/jama.285.2.171 .
doi: 10.1001/jama.285.2.171 pubmed: 11176809
Freer PE. Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics. 2015;35(2):302–15. https://doi.org/10.1148/rg.352140106 .
doi: 10.1148/rg.352140106 pubmed: 25763718
Fajardo LL, Hillman BJ, Frey C. Correlation between breast parenchymal patterns and mammographers’ certainty of diagnosis. Invest Radiol. 1988;23(7):505–8. https://doi.org/10.1097/00004424-198807000-00004 .
doi: 10.1097/00004424-198807000-00004 pubmed: 3170137
Kerlikowske K, Grady D, Barclay J, Frankel SD, Ominsky SH, Sickles EA, Ernster V. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. J Natl Cancer Inst. 1998;90(23):1801–9. https://doi.org/10.1093/jnci/90.23.1801 .
doi: 10.1093/jnci/90.23.1801 pubmed: 9839520
Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;48(Suppl 1):S30–40. https://doi.org/10.1016/j.maturitas.2004.02.012 .
doi: 10.1016/j.maturitas.2004.02.012 pubmed: 15337246
Erel CT, Elter K, Akman C, Ersavasti G, Altug A, Seyisoglu H, Ertungealp E. Mammographic changes in women receiving tibolone therapy. Fertil Steril. 1998;69(5):870–5. https://doi.org/10.1016/s0015-0282(98)00051-x .
doi: 10.1016/s0015-0282(98)00051-x pubmed: 9591495
Ozdemir A, Konuş O, Nas T, Erbaş G, Coşar S, Işik S. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet. 1999;67(1):23–32. https://doi.org/10.1016/s0020-7292(99)00102-2 .
doi: 10.1016/s0020-7292(99)00102-2 pubmed: 10576236
Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Investig. 2000;20(2):101–7. https://doi.org/10.2165/00044011-200020020-00005 .
doi: 10.2165/00044011-200020020-00005 pubmed: 23315352
Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer. 1976;37(5):2486–92.
doi: 10.1002/1097-0142(197605)37:5<2486::AID-CNCR2820370542>3.0.CO;2-8 pubmed: 1260729
Colacurci N, Fornaro F, De Franciscis P, Palermo M, del Vecchio W. Effects of different types of hormone replacement therapy on mammographic density. Maturitas. 2001;40(2):159–64. https://doi.org/10.1016/s0378-5122(01)00232-8 .
doi: 10.1016/s0378-5122(01)00232-8 pubmed: 11716994
Lundström E, Christow A, Kersemaekers W, Svane G, Azavedo E, Söderqvist G, Mol-Arts M, Barkfeldt J, von Schoultz B. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002;186(4):717–22. https://doi.org/10.1067/mob.2002.121896 .
doi: 10.1067/mob.2002.121896 pubmed: 11967497
Bruce D, Robinson J, McWilliams S, Reddy M, Fentiman I, Rymer J. Long-term effects of tibolone on mammographic density. Fertil Steril. 2004;82(5):1343–7. https://doi.org/10.1016/j.fertnstert.2004.03.063 .
doi: 10.1016/j.fertnstert.2004.03.063 pubmed: 15533357
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–27. https://doi.org/10.1016/s0140-6736(03)14065-2 .
doi: 10.1016/s0140-6736(03)14065-2 pubmed: 12927427
Whitehead M, Farmer R. The million women study: a critique. Endocrine. 2004;24(3):187–93. https://doi.org/10.1385/ENDO:24:3:187 .
doi: 10.1385/ENDO:24:3:187 pubmed: 15542884
Velthuis-Te Wierik EJ, Hendricks PT, Martinez C. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. Menopause. 2007;14(3 Pt 1):518–27. https://doi.org/10.1097/01.gme.0000247012.54468.75 .
doi: 10.1097/01.gme.0000247012.54468.75 pubmed: 17224856
Suissa S, Opatrny L. Commentary on ‘Hormone replacement therapy use and variations in the risk of breast cancer’. BJOG. 2008;115(7):918. https://doi.org/10.1111/j.1471-0528.2008.01733.x .
doi: 10.1111/j.1471-0528.2008.01733.x pubmed: 18485173
Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG. 2008;115(2):169–75; discussion 175. https://doi.org/10.1111/j.1471-0528.2007.01520.x .
doi: 10.1111/j.1471-0528.2007.01520.x pubmed: 18081598
Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—data from LIBERATE trial. Maturitas. 2011;70(4):365–72. https://doi.org/10.1016/j.maturitas.2011.09.003 .
doi: 10.1016/j.maturitas.2011.09.003 pubmed: 22030384
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D’Amico R, Bassi C, Maestri E. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10(10):CD008536. https://doi.org/10.1002/14651858.CD008536.pub3 .
doi: 10.1002/14651858.CD008536.pub3 pubmed: 27733017
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–68.
doi: 10.1016/S0140-6736(19)31709-X pmcid: 6891893
International Menopause Society. Comment on: Type and timing of menopausal hormone therapy and breast cancer risk: individual participant metaanalysis of the worldwide epidemiological evidence [Internet]. 2019. [cited 2020 Mar 22]. Available from: https://www.imsociety.org/manage/images/pdf/5054afeb9b1bc763032333443f1c0bed.pdf .
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. https://doi.org/10.1136/bmj.m3873 .
doi: 10.1136/bmj.m3873 pubmed: 33115755 pmcid: 7592147
Baek JK, Kim HI, Kang MJ, Seon KE, Kim EH, Seo SK. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric. 2022;25(5):516–22. https://doi.org/10.1080/13697137.2022.2077096 .
doi: 10.1080/13697137.2022.2077096 pubmed: 35674251

Auteurs

Stefano Lello (S)

Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito, 1, 00168, Rome, Italy.

Anna Capozzi (A)

Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito, 1, 00168, Rome, Italy. anna.capozzi@guest.policlinicogemelli.it.
ORCID: 0000-0003-0488-1215

Giovanni Scambia (G)

Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito, 1, 00168, Rome, Italy.

Gianluca Franceschini (G)

Multidisciplinary Breast Centre, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito, 1, 00168, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tibolone and Breast Tissue: a Review.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Modulateurs des récepteurs des oestrogènes › Tibolone and Breast Tissue: a Review.
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Norstéroïdes › Norprégnanes › Norprégnènes › Tibolone and Breast Tissue: a Review.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Hormonothérapie substitutive › Tibolone and Breast Tissue: a Review.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tibolone and Breast Tissue: a Review.